RA Capital Management and Forbion led a $100m Series A round in Navigator Medicines.

RA Capital Management, an investment firm, and Forbion, a venture capital firm, led a $100m Series A round in Navigator Medicines, a privately-held biotech company. “I am thrilled to join Navigator at this exciting time to advance NAV-240 through the clinic and we are deeply grateful for the support of our partner, IMBiologics, and our investors. NAV-240 has the potential to make an impact on patients living with autoimmune diseases, and our Series A funding will be pivotal in accelerating its development alongside other exciting programs within our pipeline. We look forward to initiating additional clinical studies with NAV-240 in the coming months and delivering on our commitment to innovation that enhances patient care," Dr. Dana McClintock, Navigator CMO.